ClinicalTrials.gg
RecruitingNCT07216820Updated Jan 28, 2026

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure

An interventional study of Ultrasound-Guided Interscalene Brachial Plexus Block and Phrenic-Sparing Block Combination (Experimental) in Shoulder Surgery and Obesity, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Obesity by University of North Carolina, Chapel Hill — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of North Carolina, Chapel Hill.

Planned enrollment
42nd of 67
68 · median 104
Started
2026
with 3 others
No phase
60 of 70
5 open now
Registered
68th of 70
by date

Among the 70 studies in Obesity by University of North Carolina, Chapel Hill, this one is the 42nd largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2026, is one of 60 with no phase, and was the 68th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 70 studies in Obesity by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Obesity by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a phrenic-sparing nerve block can lower early breathing problems after shoulder surgery in adults with obesity, and whether a simple breathing-strength test (maximum inspiratory pressure, MIP) helps identify who is at higher risk. The main questions are:

Does the phrenic-sparing approach reduce breathlessness or oxygen need in the recovery room (30-60 minutes after arrival)? Do patients have similar pain control and opioid use compared with the standard interscalene block (ISB)? Are there any breathing-related complications or unplanned admissions within 24 hours? Researchers will compare the phrenic-sparing block (infraclavicular + distal suprascapular) to the standard ISB, both commonly used at UNC.

Participants will:

Have a quick MIP breath test before surgery (and, if age ≥65, a brief thigh muscle ultrasound).

Be randomly assigned to receive either the standard ISB or the phrenic-sparing block (both ultrasound-guided and part of routine care).

Receive usual anesthesia/surgery; have a brief recovery check at 30-60 minutes (breathlessness score, oxygen use, oxygen level).

Have pain medicines recorded from anesthesia start to PACU discharge; the team may review the chart up to 24 hours and make a short follow-up call (24-48 hours).

03

Conditions studied

  • Shoulder Surgery
  • Obesity

Browse trials for

Keywords

  • interscalene block
  • phrenic-sparing block
  • brachial plexus block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years (self-report, confirmed on chart).
  • Body-mass index ≥ 35 kg m\^2 at the pre-operative clinic visit (chart).
  • Scheduled for elective unilateral shoulder surgery (arthroscopy, arthroplasty, rotator cuff repair, reverse arthroplasty) under general anesthesia at UNC Hospitals
  • Planned use of a single-injection regional brachial-plexus block for postoperative analgesia (anesthesia record).
  • Able to perform a maximal-inspiratory-pressure (MIP) maneuver at screening, producing two reproducible efforts (bedside test)
  • Able to read or understand English and provide written (consent discussion).

Exclusion criteria

Exclusion Criteria:

  • Emergent or trauma shoulder procedure or case converted to open surgery (schedule/chart).
  • Pregnancy confirmed by point-of-care urine test on day of surgery (POC test). Prisoner status or legal incapacity to consent (chart/interview).
  • Severe pulmonary disease: GOLD stage 3-4 , restrictive lung disease unrelated to obesity with FVC \< 50 % predicted, baseline dyspnea Borg ≥ 3, or home oxygen therapy (pulmonary clinic notes, patient interview).
  • Severe heart disease- Severe valvular heart disease, Congestive Heart Failure Class III or IV, Obstructive Coronary Artery Disease with Angina
  • Neuromuscular disorders affecting respiratory muscles (e.g., ALS, myasthenia gravis) or known diaphragmatic paralysis (chart).
  • Coagulopathy ( \< 100 × 10/ L or > 1.5) or local infection at block sites (pre-op labs/assessment).
  • Anemia and hemoglobinopathies: \<10 g/dl, hemoglobinopathy.
  • Allergy to bupivacaine, dexamethasone, or ultrasound gel (self-report).
  • Chronic opioid use > 100 mg oral-morphine equivalents per day in the three months preceding surgery (medication history, PDMP query).
  • Prior enrolment in this trial or planned participation in another interventional study that might confound outcomes (research registry).
  • Anticipated inability to comply with postoperative assessments (e.g., profound cognitive impairment, expected early transfer to outside facility) as judged by the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Standard Interscalene Block

    Standard Interscalene Brachial Plexus Block (Control) Description: Participants receive a single 16 mL interscalene block at the C5-C6 level under ultrasound guidance. The injectate contains 15 mL of 0.5% bupivacaine HCl (75 mg) mixed with 1 mL preservative-free dexamethasone (4 mg).

    Procedure: Ultrasound-Guided Interscalene Brachial Plexus Block · Drug: Bupivacaine HCl 0.5% Injectable Solution · Drug: Dexamethasone 4mg

  • Experimental
    Arm 2: Phrenic-Sparing Block Combination

    Combined Infraclavicular + Distal Suprascapular Block (Phrenic-Sparing Technique) Description: Participants receive two ultrasound-guided peripheral nerve blocks designed to minimize phrenic nerve involvement: Infraclavicular block: 15 mL 0.5% bupivacaine + 1 mL dexamethasone (total 16 mL) Distal suprascapular block: 12 mL 0.5% bupivacaine + 1 mL dexamethasone (total 13 mL) Total local-anesthetic dose = 135 mg bupivacaine + 8 mg dexamethasone, within accepted safety limits.

    Procedure: Phrenic-Sparing Block Combination (Experimental) · Drug: Bupivacaine HCl 0.5% Injectable Solution · Drug: Dexamethasone 4mg

Interventions

  • ProcedureUltrasound-Guided Interscalene Brachial Plexus Block

    Single 16 mL injection (15 mL 0.5 % bupivacaine + 1 mL dexamethasone 4 mg) at the C5-C6 root level under ultrasound guidance. Performed pre-operatively as standard care for shoulder surgery. Arm Cross-Reference: Standard Interscalene Block (Control)

  • ProcedurePhrenic-Sparing Block Combination (Experimental)

    Infraclavicular: 15 mL (75 mg) 0.5 % bupivacaine + 1 mL dexamethasone (4 mg) injected around the cords of the brachial plexus beneath the clavicle under ultrasound guidance. Distal Suprascapular: 12 mL (60 mg) 0.5 % bupivacaine + 1 mL (4 mg) dexamethasone injected at the suprascapular notch under ultrasound guidance to provide complete shoulder coverage while minimizing phrenic nerve involvement. Total local anesthetic dose = 135 mg bupivacaine + 8 mg dexamethasone. Arm Cross-Reference: Phrenic-Sparing Block Combination (Experimental)

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infraclavicular: Adminstered as 15 mL (75 mg) injection (together with dexamethasone). Distal Suprascapular: Adminstered as 12 mL (60 mg) injection (together with dexamethasone).

    Also known as: Bupivacaine Hydrochloride Injection

  • DrugDexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Adminstered as applicable for infraclavicular and distal suprascapular: as 1 mL (4 mg) injection (together with bupicacaine 0.5%).

    Also known as: Decadron, Dexamethasone Intensol, De-Sone LA, Dxevo, Dexacorten

06

What researchers measure

Primary outcomes

  1. Incidence of Early Postoperative Respiratory Compromise

    Composite outcome defined as either (a) a Modified Borg Dyspnea Score ≥ 3 in the post-anesthesia care unit (PACU, 30-60 minutes after surgery) or (b) continued need for supplemental oxygen at the PACU assessment. Outcome Type: Primary Unit of Measure: Percentage of participants meeting composite endpoint.

    Time frame: Within 60 minutes after arrival to PACU

  2. Effect Modification by Preoperative Maximum Inspiratory Pressure (MIP)

    Assess whether the magnitude of treatment benefit from the phrenic-sparing block varies by baseline inspiratory-muscle strength. The effect is modeled as the interaction between block type and continuous MIP (cm H₂O) on the composite respiratory-compromise endpoint. Unit of Measure: Interaction odds ratio (per 10 cm H₂O decrement in MIP).

    Time frame: Baseline (preoperative MIP test) and PACU assessment (30-60 minutes post-surgery).

Secondary outcomes

  1. Lowest Oxygen Saturation (SpO₂) in PACU

    Minimum oxygen saturation recorded by pulse oximetry during the PACU stay Unit of Measure: Percent (%)

    Time frame: From PACU arrival to discharge (typically 60-120 minutes)

  2. Total Duration of Supplemental Oxygen Use

    Total number of hours on oxygen from PACU arrival until hospital discharge (maximum 24 hours). Unit of Measure: Hours.

    Time frame: 0-24 hours post-surgery.

  3. Post-Induction Opioid Consumption

    Total opioid dose administered from anesthesia induction to PACU discharge, converted to oral morphine milligram equivalents (OMME). Unit of Measure: mg OMME.

    Time frame: 0-6 hours post-surgery.

  4. Diaphragmatic Excursion Change from Baseline

    Percent change in diaphragmatic excursion (ultrasound-measured) from baseline to PACU. Unit of Measure: Percent change (%).

    Time frame: Baseline (pre-block) and 30-60 minutes post-surgery in PACU.

  5. PACU Pain Score

    Numeric Rating Scale (NRS) for pain recorded at 30-60 minutes post-surgery. Unit of Measure: 0-10 NRS scale.

    Time frame: Within 1 hour after PACU arrival.

Other outcomes

  1. Exploratory: Association of Frailty and Sarcopenia Measures With Respiratory Outcomes

    Explore whether rectus femoris index (cm/height²) or Clinical Frailty Scale (CFS) scores predict postoperative respiratory compromise in participants ≥ 65 years. Unit of Measure: Correlation coefficient or adjusted risk ratio.

    Time frame: Baseline preoperative assessment; outcome analyzed at PACU.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Time frame: beginning 9 and continuing for 36 months following publication

Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 21 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 15, 2025
StartActual
Jan 21, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 15, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216820
Collaborators
American Society of Regional Anesthesia
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Jan 21, 2026
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Monika Nanda
Contact
mnanda@aims.unc.edu
919-966-5136
Monika Nanda
principal investigator · University of North Carollina at Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion